Shares of Cyclacel Pharmaceutical (CYCC -3.9%) slide after releasing updated survival data over the weekend from its Phase III studies of its oral sapacitabine capsules, a treatement for elderly patients with newly diagnosed acute myeloid leukemia who are not candidates for chemotherapy. The data was presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs